TORONTO, Feb. 4, 2025 /PRNewswire/ — JMIR Publications, the leading open access publisher in digital health and open science, announced today that Sean Jeong has been appointed as its new chief executive officer (CEO), effective January 23, 2025. Dr Gunther Eysenbach, founder of JMIR Publications, will be stepping down as CEO after over two decades of transformative leadership to focus on new opportunities for innovation in academic publishing, including artificial intelligence (AI)-driven solutions and the advancement of Plan P. He will continue to serve as the editor in chief of the Journal of Medical Internet Research and CEO of Digital Health and Science Ventures, the holding company of JMIR Publications.
Dr Eysenbach is a pioneer in the field of open access publishing and digital health. He founded JMIR Publications in 1999 with the launch of the Journal of Medical Internet Research, one of the first open access journals. Under his leadership, JMIR Publications has grown into a globally recognized publisher, with over 30 journals and a reputation for quality and innovation. Dr Eysenbach has been recognized as the most impactful medical informatician in the world for his contributions to the field. He is a cofounder of the Open Access Scholarly Publishers Association (OASPA) and a strong advocate for open science.
“It has been an incredible journey leading JMIR Publications for the past 25 years,” said Dr Eysenbach. “I am immensely proud of what we have achieved together, building a platform that disseminates vital research in digital health and open science to a global audience. I have full confidence in Sean’s ability to guide JMIR Publications to new heights, and I am excited to continue contributing to its success in new ways, focusing on emerging technologies and initiatives like Plan P that will shape the future of academic publishing.”
Sean Jeong brings 20 years of experience in consulting, education, technology, marketing, and the nonprofit sector to his new role. He has a proven track record of success in agile delivery, digital transformation, technical strategy, and program execution. During his four years at JMIR Publications as chief product and technology officer, Jeong established the company’s product department, scaled its technology infrastructure, and oversaw financial operations.
“I am honored and excited to lead JMIR Publications into its next chapter,” said Sean Jeong. “I am deeply committed to our mission of disseminating impactful research to the widest possible audience and ensuring JMIR remains at the forefront of open access publishing in digital health. We will continue to build on the strong foundation established by Dr Eysenbach, embracing innovation and empowering our communities with knowledge.”
About JMIR Publications
JMIR Publications is a leading open access publisher of digital health research and a champion of open science. With a focus on author advocacy and research amplification, JMIR Publications partners with researchers to advance their careers and maximize the impact of their work. As a technology organization with publishing at its core, we provide innovative tools and resources that go beyond traditional publishing, supporting researchers at every step of the dissemination process. Our portfolio features a range of peer-reviewed journals, including the renowned Journal of Medical Internet Research.
To learn more about JMIR Publications, please visit jmirpublications.com or connect with us via BlueSky, LinkedIn, YouTube, Facebook, and Instagram.
Head office: 130 Queens Quay East, Unit 1100, Toronto, ON, M5A 0P6 Canada
Media contact: communications@jmir.org
The content of this communication is licensed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, published by JMIR Publications, is properly cited.
Media Contacts: Jane Kelly
Integrated Marketing Manager
jane.kelly@jmir.org
“This news release was issued on behalf of Newswise™. For more information, visit http://www.newswise.com.”
SOURCE JMIR Publications
Vancouver, British Columbia--(Newsfile Corp. - February 9, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF)…
This groundbreaking discovery has revealed a systemic metabolic dysfunction that creates a toxic exosome cargo…
This groundbreaking discovery has revealed a systemic metabolic dysfunction that creates a toxic exosome cargo…
Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint…
Label-verified GaraHerb ingredient disclosures, manufacturing and policy transparency details, and what consumers searching for GaraHerb…
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES…